baber/WOPTO huggingface dataset:
Patent NZ-542848-A (NZ)
Title: Concrete curing blanket
Inventor: MCDONALD STEPHEN F
Filed: 2005-10-06
Abstract: Curing blanket having a clear or transparent first layer and a second layer airlaid on the first layer. Another embodiment has a first layer, a second layer airlaid on the first layer, and a third layer disposed on the second layer, with the second layer interposed between the first layer and the third layer. The first layer and the second layer are thermally bonded and/or latex bonded. The third layer includes a polymer release agent composed of bi-component fibres. The first layer contacts curing concrete when the blanket is disposed thereon.
Patent NZ-545075-A (NZ)
Title: Fungicidal mixtures of a triazolopyrimidine derivative and epoxiconazole
Inventor: TORMO I BLASCO JORDI
IPC: A01N43/90
Filed: 2004-07-07
Abstract: Disclosed are fungicidal mixtures containing (1) a triazolopyrimidine derivative of formula (I) and (2) epoxiconazole of formula (II) as active components at a synergistically effective quantity, a method for controlling harmful fungi of the class Oomycetes by means of mixtures of compound (I) and compound (II), the use of compound (I) along with compound (II) for producing such mixtures, and agents containing said mixtures.
Patent NZ-553945-A (NZ)
Title: Process for plasmid DNA fermentation
Inventor: CARNES AARON E
IPC: C12P19/34
Filed: 2005-08-16
Abstract: Provided is a method for fed-batch fermentation production of covalently closed supercoiled plasmid DNA comprising the steps of a) growing the bacterial cells containing a plasmid, cosmid, or bacterial artificial chromosome replicon at a reduced temperature during the fed-batch phase and b) restricting growth rate during the fed-batch phase by nutrient limitation; and c) inducing plasmid production by temperature up shift: and d) continuing growth at elevated temperature to accumulate plasmid product.
Patent NZ-555484-A (NZ)
Title: An applicator
Inventor: BELL STEVEN JOHN
Filed: 2007-05-30
Abstract: An applicator to apply two uniform continuous beads of adhesive or plaster simultaneously to a wall and ceiling of a room, so that a cove or mould may be affixed to cover the join, is disclosed.
Patent NZ-555494-A (NZ)
Title: Method for transporting people in a building
Inventor: FINSCHI LUKAS
IPC: B66B1/18
Filed: 2005-11-28
Abstract: A method of transporting persons in a multi-storey building by means of a lift installation is provided. The method includes at least one lift cage (11), where the lift cage is entered by persons at at least one first access storey (S1). One destination storey (S4, S5) is fixedly allocated to the access storey, which is the most likely travel destination of a person in the part of the building at which the lift is located. An arrangement using the method is also provided.
Patent NZ-556182-A (NZ)
Title: Method for producing pteridine and annelated piperazin-2-one derivatives and intermediates of said method
Inventor: DURAN ADIL
IPC: C07D475/00
Filed: 2005-11-29
Abstract: Disclosed is a process for preparing pteridine and condensed piperazin-2-one derivatives of general formula I (wherein the substituents are disclosed herein), in which a compound of formula II is a) hydrogenated with hydrogen in the presence of a hydrogenation catalyst (selected from the group consisting of rhodium, ruthenium, iridium, platinum, palladium and nickel), and b) a copper, iron or vanadium compound is added, wherein steps a) and b) may take place simultaneously or successively. Also disclosed is an intermediate product of formula III which is obtained after the first step a), and which may optionally be isolated. Additionally, the compound (7R)-2-chloro-7-ethyl-8-isopropyl-7,8-dihydro-5H-pteridin-6-one is further disclosed.
Patent NZ-562227-A (NZ)
Title: Operating a pump by sensing operating values and controlling a variable frequency drive to fulfil predetermined conditions
Inventor: ZHONG ZHIYONG
IPC: F04B49/06
Filed: 2006-06-15
Abstract: Disclosed is a method for operating a pump (1) comprising variable frequency drive means. The method for includes obtaining values of operating parameters of the pump indicating pump conditions; communicating said values of operating parameters from variable frequency drive means (2) to a control device (11); determining if a predetermined condition is fulfilled; and communicating instructions from the control device to the variable frequency drive means based on the fulfilment of said predetermined condition.
Patent NZ-563863-A (NZ)
Title: Agent for regeneration and/or protection of nerves
Inventor: OHMOTO KAZUYUKI
IPC: A61K31/426
Filed: 2006-06-02
Abstract: The disclosure relates to an compound of formula (I-3) which is an agent for regeneration and/or protection of nerves. More particularly, it relates to an agent for regeneration and/or protection of nerves comprising an EP2 agonist which may have an EP3 agonistic effect. The compound of formula (I-3) is therefore useful as a therapeutic agent for a disease of the peripheral nervous system, such as a lower or upper motor neuron disease, a nerve root disease, plexopathy, thoracic outlet compression syndrome, peripheral neuropathy, neurofibromatosis and neuromuscular transmission disease. An EP2 agonist which has an EP3 agonistic effect is a safe and effective agent for the regeneration and/or protection of nerves which has little influence on the circulatory system.
Patent NZ-568202-A (NZ)
Title: Character inputting device
Inventor: OH EUI-JIN
IPC: G06F3/02
Filed: 2006-11-10
Abstract: A character input device comprises an input means for enabling direction movement input and direction pressing input; a movement input detector for detecting the direction movement input; a pressing input detector for detecting the direction pressing input; and a controller for extracting characters from a memory for execution. The characters correspond to a result of detection performed by the movement input detector and the pressing input detector. The direction movement input and the direction pressing input are respectively independently performed, and the direction movement input and the direction pressing input are simultaneously performed or the direction movement input or the direction pressing input is performed before the input unit returns to an original position in a state that the direction movement input or the direction pressing input has been performed.
Patent NZ-570471-A (NZ)
Title: A side of a polygonal aperture to be cut has two saw blades of different cutting plates in close proximity
Inventor: BURNS ALEXANDER
IPC: B23D49/00
Filed: 2007-01-26
Abstract: Disclosed is a cutting device for cutting through a work substrate. The cutting device comprises a plurality of cutting plates (101a, 101b, 102a, 102b), at least one of the plates having at least one linear saw blade (110a, 110b,) with a cutting edge (111) for cutting through the substrate. The cutting plates at least partially overlie each other, with their saw blades directed forward to be presented against the substrate. The plates are arranged such that the saw blades define the outline of an aperture that is to be cut. The plates are capable of a reciprocating linear movement so that their cutting edges cut the substrate, the movement being effected by an eccentric cam arrangement (120, 121) associated with a rotating drive shaft (100). A side of the aperture to be cut has two saw blades in close proximity, each blade associated with a different plate.
Patent NZ-571426-A (NZ)
Title: Aqueous composition comprising castor oil, a 15-keto-prostaglandin compound and a quaternary ammonium cationic surface active agent
Inventor: HIRATA RYU
IPC: A61K9/08
Filed: 2007-03-12
Abstract: Disclosed is an aqueous composition comprising a 15-keto-prostaglandin compound as the sole active ingredient and a polyoxyethylene castor oil derivative, wherein the composition does not comprise any surface active agent other than a polyoxyethylene castor oil derivative and a quaternary ammonium type cationic surface active agent.
Patent NZ-573307-A (NZ)
Title: 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor
Inventor: SAVORY EDWARD DANIEL
IPC: A61K31/52
Filed: 2007-06-26
Abstract: Disclosed is a compound selected from (2R,3R,4R,5R)-5-[6-amino-2-(cyclopentylmethoxy)-9H-purin-9-yl]-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol, (2R,3R,4R,5R)-5-{ 6-amino-2-[(2,2,3,3-tetrafluorocyclobutyl)oxy]-9H-purin-9-yl} -2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol, (2R,3R,4 R,5R)-5-[6-amino-2-(2,5-difluorophenoxy)-9H-purin-9-yl]-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol, (2R,3R,4R,5R)-5-[6-amino-2-(3,4-difluorophenoxy)-9H-purin-9-yl]-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol; (2R,3R,4R,5R)-5-[6-amino-2-[4-chloro-3-(trifluoromethyl)phenoxy]-9H-purin-9-yl]-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol,(2R,3R,4R,5R)-5-(6-amino-2-{ [(1S)-1-methylpropyI]amino} -9H-purin-9-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol; and (2R,3R,4R,5R)-5-[6-amino-2-(cyclohexylamino)-9H-purin-9-yl]-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol for treating pain and inflammation.
Patent NZ-577023-A (NZ)
Title: Rupturable pressure release element for electrical transformer
Inventor: MAGNIER PHILIPPE
IPC: H01F27/40
Filed: 2006-10-27
Abstract: A device and method for preventing an explosion of a member in an electric transformer (1) including a vessel (2) containing a combustible cooling fluid. The device includes a pressure relief member (14) for depressurising the vessel, and a bag (8) provided downstream and capable of expanding from a flat state to an inflated state upon rupture of the pressure relief member for confining the fluid.
Patent NZ-580235-A (NZ)
Title: A method for selecting responders to blockade of integrin receptors
Inventor: MARJAMAKI ANNE
IPC: C12Q1/68
Filed: 2008-04-16
Abstract: Provided is a method for identifying a subject belonging to a group responding to a blockade of alpha2beta1 integrin receptors as determined by a decrease in platelet aggregation, comprising a) determining a single nucleotide polymorphism (SNP) C/T located at base pair 807 of alpha2 integrin cDNA, in a sample obtained from said subject, b) measuring the expression level of alpha2beta1 integrin on platelets obtained from a subject having a CT807 genotype, and c) identifying as a subject responding to the blockade of alpha2beta1 integrin receptors , a subject having either a TT807 genotype, or having a CT807 genotype combined with a high expression level of alpha2beta1 integrin, wherein high expression level of aplha2beta1 integrin means a statistically significant increase in said expression level as compared to the expression level of alpha2beta1 integrin in subjects having a CC807 genotype.
Patent NZ-580565-A (NZ)
Title: Microfluidic device and leucocyte antigen mediated microfluidic assay
Inventor: RODRIGUEZ RODOLFO RAMIRO
IPC: B32B5/02
Filed: 2005-05-13
Abstract: Disclosed is a leucocyte antigen mediated microfluidic assay for testing a leucocyte containing fluid from a subject for prior exposure to a predetermined antigen which would have caused the leucocyte to become presensitized to the antigen comprising: performing a first test comprising the steps of: a) placing a microvolume first sample of the subjects leucocyte containing fluid in a first sample microchamber; b) transporting the first sample to a first reaction microchamber containing the predetermined antigen and an antigen accelerator and allowing them to react together for a predetermined time; c) transporting the reacted first sample to a first observation microchamber; d) mixing one or more leucocyte observation colorants with the reacted first sample during transportation to the observation microchamber or in the observation microchamber; e) optically performing an optical scan of the reacted sample in the first observation microchamber under conditions which allow the measurement of at least 1 measurement factor of the leucocytes in the reacted first sample; performing a second test comprising the steps of: a) placing a microvolume second sample of the subjects leucocyte containing fluid in a second sample microchamber; b) transporting the second sample to an antigen free second reaction microchamber containing the same antigen accelerator as the first test and allowing them to react for the predetermined time; c) transporting the second sample to a second observation microchamber; d) mixing the same leucocyte observation colorants as the first test with the reacted second sample during transport to the second observation microchamber or in the second observation microchamber; e) optically performing an optical scan of the reacted second sample in the second observation microchamber under conditions that allow the measurement of the same leucocyte measurement factors measured in the first test; comparing the results of the first test scan to the second test scan to determine if any differences between the two scans are due to a leucocyte-antigen mediated response and wherein the assay excludes an optical scan achieved by multi- wavelength fluorescence image analysis. Also disclosed is a similar method where the respective reaction and observation chambers are the same. (62) Divided Out of 552034
Patent NZ-582725-A (NZ)
Title: Cooling a Foodstuff
Inventor: FLOREY LINDA KAY
IPC: A23B7/04
Filed: 2010-01-20
Abstract: A method of facilitating the cooling of a foodstuff, comprises placing the foodstuff in a container such that it surrounds a ventilation shaft 2 in a central part of the container, the ventilation shaft 2 having an opening or openings 5 open to the foodstuff such that heat from the foodstuff in the inner medial parts of the container escapes from the container via the shaft 2.
Patent NZ-587357-A (NZ)
Title: Control circuit for pick-up in inductive power transfer system selectively shunts diodes in rectifier bridge to reduce transient disturbances to primary current
Inventor: COVIC ANTHONY GRANT
IPC: H01F38/00
Filed: 2010-08-13
Abstract: Disclosed is an inductive power transfer pick-up controller. The controller is comprised of an input for receiving an AC current (IL3) from a resonant circuit, an output for supplying a DC current to a load, and a control circuit. The control circuit is electrically coupled to the input and the output. The control circuit is comprised of a diode bridge (formed from D1, D2, D3 and D4), shunting switches (S1 and S2), and control means. The control means are provided for selectively operating the switches (S1 and S2) to shunt first and second diodes (D1 and D2) of the diode bridge in synchrony with the AC current (IL3).
Patent NZ-587462-A (NZ)
Title: Reinforced optical fiber cable with two strengthening members with one in the core and the other in the sheath
Inventor: OSATO KEN
IPC: G02B6/44
Filed: 2009-02-18
Abstract: An optical fibre cable 1 having an axis, comprises a slotted core 7 elongated along the axis that includes a slot 11 running in parallel with the axis and a groove 5 accessible through the slot 11, one or more optical fibres 3 placed in the groove 5, a sheath 9 enclosing the slotted core 7 and the optical fibres, and a bonding portion where the slotted core 7 is bonded with the sheath 9. The bonding portion ranges over the slotted core 7 in parallel with the axis opposite to the slot 11 of the core member. The cable 1 further comprises a first strength member 17 embedded in the slotted core 7 and running in parallel with the axis, and a second strength member 13 embedded in the sheath 9 and running in parallel with the axis, where the first and second strength members are aligned on a plane 13 that includes the axis.
Patent NZ-597977-A (NZ)
Title: Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
Inventor: TALLBERG THOMAS
IPC: A61K33/24
Filed: 2008-12-17
Abstract: Disclosed is the use of a) neurogenic CNS lipids b) L-amino acids arginine (Arg) or lysine (Lys) and leucine (Leu), c) trace elements chromium (Cr), tin (Sn), selenium (Se), strontium (Sr), vanadium (V), and tungsten (W), and d) folic acid for the manufacture of a pharmaceutical composition for treating or preventing sterile inflammation causing rheumatism.
Patent NZ-611151-A (NZ)
Title: Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
Inventor: RODGERS JAMES D
IPC: C07D487/04
Filed: 2011-11-18
Abstract: The disclosure relates to a family of compounds as shown in Formula I, wherein A, L, W, X, Y, Z, R1, R2, R3 and R5 are as disclosed in the specification. These cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives are useful as Janus kinase (JAK) inhibitors. The disclosure also relates to a method of treating an autoimmune disease, a cancer, a myeloproliferative disorder, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of these compounds. Examples of these compounds include: 4-{ cis-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} -N-[(1R)-1-methylpropyl]piperazine-1-carboxamide; { cis-3-(4-{ [6-(azetidin-1-ylmethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy} piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile; { trans-3-(4-{ [4-(1-hydroxy-1-methylethyl)-6-(trifluoromethyl)pyridin-2-yl]carbonyl} piperazin-1-yl)-1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile; { trans-3-(4-{ [6-(1-hydroxy-1-methylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl} piperazin-1-yl)-1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-1-yl]cyclobutyl} acetonitrile.
Patent NZ-613249-A (NZ)
Title: Use of propylene glycol to control the degree of heat-induced foam generation in a food system
Inventor: ALEXANDER JESSE
IPC: A23L13/00
Filed: 2012-03-12
Abstract: The disclosure relates to the use of a composition to control the degree of heat-induced foam generation in a foodstuff system when said foodstuff system is heated, wherein the composition comprises a fatty acid ester of propylene glycol. The fatty acid ester of propylene glycol may be propylene glycol monostearate. The composition may further comprise polyglycerol polyricinoleic acid or a mono-diglyceride. The disclosure also relates to these compositions and foodstuffs comprising these compositions.
Patent NZ-628124-A (NZ)
Title: Pharmaceutical compositions to reduce complications of ocular steroid
Inventor: HONG KEELUNG
IPC: A61P27/02
Filed: 2013-02-08
Abstract: The disclosure relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid preferably dexamethasone sodium phosphate, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5umol per 50ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
Patent NZ-630238-A (NZ)
Title: Irradiation device
Inventor: GROSETH MORTEN
IPC: A61N5/06
Filed: 2014-04-09
Abstract: Disclosed is an irradiation device for insertion into an orifice of the body to provide photodynamic therapy. The device includes of a housing moulded from a resilient material and adapted to be fully inserted and secured in the orifice. The housing encloses an LED lamp system and a power source for powering the LED lamp system. The device is independently operational while located in the orifice. The housing comprises a first housing part for holding the power source and a second housing part for holding the LED lamp system, the first and second housing parts being separable and preferably being formed separately from the LED lamp system. The first housing part consists of a chamber for holding the power source and an opening into the chamber is provided through a resilient opening part, wherein the chamber is closed when the first housing part is joined to the second housing part.
Patent NZ-711254-A (NZ)
Title: Talen-based gene correction
Inventor: OSBORN MARK
IPC: A01H1/06
Filed: 2014-02-28
Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of a mutated COL7A1 gene in patients with Epidermolysis bullosa (EB). Epidermolysis bullosa (EB) is a group of genetic conditions that cause the skin to be very fragile and to blister easily. Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching. Recessive dystrophic epidermolysis bullosa (RDEB), the most severe and classical form of the disease, is characterized by extensive blistering and scarring of the skin and mucosal membranes.
Patent NZ-711669-A (NZ)
Title: Electrode configurations for an implantable electroacupuncture device
Inventor: PETERSON DAVID K L
IPC: A61N1/05
Filed: 2014-03-11
Abstract: Some previously proposed implantable electroacupuncture devices (IEADs) are too invasive and/or provide ineffective treatment. Disclosed here in is an IEAD (900) for generating electroacupuncture (EA) stimulation pulses that are applied substantially at or near a specified target tissue location. The IEAD comprises a housing, cathodic electrodes (910) and anodic electrodes (906), stimulation circuitry, and a coin-cell type primary battery. The housing has a thickness of no greater than about 2.5 mm. The cathodic and anodic electrodes (910, 906) form an integral part of the housing. The stimulation circuitry resides inside the housing and is electrically coupled to the cathodic and anodic electrodes (910, 906), wherein the stimulation circuitry generates EA stimulation pulses that are delivered to the target location through the cathodic and anodic electrodes (910, 906) in accordance with a prescribed stimulation regimen, wherein said stimulation regimen defines the duration and rate at which a stimulation session is applied, said stimulation regimen requiring that the stimulation session have a duration of T3 minutes and a rate of occurrence of once every T4 minutes, wherein the ratio of T3/T4 is no greater than 0.05, and wherein during each stimulation session EA stimulation pulses having one or more specified widths and amplitudes are generated at one or more specified rates. The coin-cell type primary battery resides inside the housing that provides the operation power for the stimulation circuitry, wherein the primary battery has an internal impedance greater than 5 ohms. The cathodic electrodes (910) are located on a top or bottom surface (902, 908) of the housing and positioned no closer than 5 mm from the closest edge of the nearest at least one anodic electrode (906), and wherein the total surface area of the cathodic electrodes (910) is no smaller than about 0.5 mm2, and wherein the positioning and surface area of the cathodic electrodes (910) are selected to allow a desired current density to flow through the electrodes surface area without causing electrode corrosion or current shunting.
Patent NZ-739165-A (NZ)
Title: Human cd3 binding antibody
Inventor: BAKKER ALEXANDER BERTHOLD HENDRIK
IPC: A61K39/395
Filed: 2016-07-08
Abstract: The disclosure relates to human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence: QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof The disclosure also relates to with bispecific antibodies that have a heavy chain as defined herein above. Methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody are provided.